Scarica l'app Stockscreener
5.78
1.37%
-0.08
Dopo l'orario di chiusura:
5.78
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché ACRS Giù?
Forum
Previsione
Precedente Chiudi:
$5.86
Aprire:
$5.82
Volume 24 ore:
666.22K
Relative Volume:
0.38
Capitalizzazione di mercato:
$850.81M
Reddito:
$8.37M
Utile/perdita netta:
$-69.66M
Rapporto P/E:
-10.31
EPS:
-0.5604
Flusso di cassa netto:
$-51.45M
1 W Prestazione:
-2.20%
1M Prestazione:
+6.45%
6M Prestazione:
+81.19%
1 anno Prestazione:
+242.01%
Intervallo 1D:
$5.64
$5.855
Intervallo di 1 settimana:
$5.64
$6.055
Portata 52W:
$1.70
$6.515
Aclaris Therapeutics Inc Stock (ACRS) Company Profile
Nome
Aclaris Therapeutics Inc
Settore
Industria
Telefono
484-324-7933
Indirizzo
701 LEE ROAD, WAYNE, PA
Compare ACRS vs VRTX, REGN, ARGX, RVMD, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ACRS
Aclaris Therapeutics Inc
|
5.78 | 859.64M | 8.37M | -69.66M | -51.45M | -0.5604 |
VRTX
Vertex Pharmaceuticals Inc
|
505.75 | 133.25B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
803.48 | 82.16B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
851.29 | 54.80B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
203.71 | 43.99B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
347.48 | 40.62B | 5.76B | 514.49M | 1.10B | 4.4813 |
Aclaris Therapeutics Inc Stock (ACRS) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-04-16 | Iniziato | Oppenheimer | Outperform |
| 2025-07-10 | Ripresa | Piper Sandler | Overweight |
| 2025-05-28 | Iniziato | Wedbush | Outperform |
| 2025-03-18 | Ripresa | Cantor Fitzgerald | Overweight |
| 2024-12-23 | Aggiornamento | H.C. Wainwright | Neutral → Buy |
| 2024-11-20 | Aggiornamento | Cantor Fitzgerald | Neutral → Overweight |
| 2024-11-19 | Aggiornamento | BTIG Research | Neutral → Buy |
| 2024-11-19 | Aggiornamento | Jefferies | Hold → Buy |
| 2024-11-19 | Aggiornamento | Leerink Partners | Market Perform → Outperform |
| 2024-11-18 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2024-01-22 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2023-11-13 | Downgrade | William Blair | Outperform → Mkt Perform |
| 2023-10-03 | Iniziato | Evercore ISI | Outperform |
| 2022-12-14 | Iniziato | Stifel | Buy |
| 2022-12-01 | Iniziato | Goldman | Buy |
| 2022-10-06 | Iniziato | BTIG Research | Buy |
| 2021-07-23 | Ripresa | Jefferies | Buy |
| 2021-06-15 | Iniziato | Piper Sandler | Overweight |
| 2021-04-21 | Iniziato | H.C. Wainwright | Buy |
| 2019-10-22 | Aggiornamento | SVB Leerink | Mkt Perform → Outperform |
| 2019-09-06 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| 2019-06-27 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| 2019-05-06 | Iniziato | SVB Leerink | Outperform |
| 2018-03-28 | Ripresa | Leerink Partners | Outperform |
| 2018-02-09 | Iniziato | Guggenheim | Buy |
| 2017-06-16 | Iniziato | Cantor Fitzgerald | Overweight |
| 2016-11-29 | Iniziato | Leerink Partners | Outperform |
| 2016-09-30 | Iniziato | JMP Securities | Mkt Outperform |
| 2016-06-10 | Iniziato | Guggenheim | Buy |
| 2015-11-02 | Iniziato | Citigroup | Buy |
| 2015-11-02 | Iniziato | Jefferies | Buy |
Mostra tutto
Aclaris Therapeutics Inc Borsa (ACRS) Ultime notizie
Sei Investments Co. Makes New Investment in Aclaris Therapeutics, Inc. $ACRS - marketbeat.com
Dimensional Fund Advisors LP Has $1.91 Million Stock Position in Aclaris Therapeutics, Inc. $ACRS - marketbeat.com
FDA Fast Track Status Advances Aclaris Lichen Planus Drug - mychesco.com
HC Wainwright Has Pessimistic Outlook of ACRS Q3 Earnings - marketbeat.com
Renaissance Technologies LLC Has $1.89 Million Stake in Aclaris Therapeutics, Inc. $ACRS - marketbeat.com
Aclaris Therapeutics, Inc. (ACRS) stock price, news, quote and history - Yahoo Finance Australia
Aclaris Raises Capital as Drug Pipeline Spending Accelerates - MyChesCo
Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Given Average Rating of "Buy" by Brokerages - marketbeat.com
Aclaris Therapeutics, Inc. (ACRS) Stock Price, News, Quote & History - Yahoo! Finance Canada
Wall Street Analysts Believe Aclaris (ACRS) Could Rally 69.2%: Here's is How to Trade - Zacks Investment Research
Weekly Recap: Q2 loss, runway into 2028 and Fast Track for modzatinib - TradingView
Aclaris Therapeutics (ACRS) Stock Drifts Lower As Losses Deepen On Thin Revenue - simplywall.st
Aclaris Updates At-The-Market Equity Sales Agreement - theglobeandmail.com
Aclaris Therapeutics (NASDAQ:ACRS) Stock Price Down 6%Here's What Happened - marketbeat.com
US FDA Fast-tracks Aclaris’ Modzatinib for Lichen Planus - The Dermatology Digest
FDA grants fast track status to Aclaris’ lichen planus drug By Investing.com - Investing.com Nigeria
Craig-Hallum Maintains Aclaris Therapeutics(ACRS.US) With Buy Rating, Maintains Target Price $10 - Moomoo
Aclaris Therapeutics Inc (8AT.MU) Analyst insights, Price targets and Recommendations - Yahoo Finance Australia
Aclaris Therapeutics (NASDAQ:ACRS) Releases Quarterly Earnings Results, Beats Expectations By $0.01 EPS - MarketBeat
Aclaris Therapeutics (ACRS) Releases Q2 2026 Earnings: Revenue Declines, Losses Narrow - quiverquant.com
FDA grants fast track status to Aclaris’ lichen planus drug - Investing.com
Aclaris Therapeutics Receives Fast Track Designation for Modzatinib (ATI-2138) for Moderate to Severe Lichen Planus (LP) - Yahoo Finance
Aclaris Therapeutics (NASDAQ: ACRS) widens loss as R&D spending accelerates - Stock Titan
Form 8K Aclaris Therapeutics Inc For: 6 August By Investing.com - Investing.com South Africa
Aclaris Therapeutics, Inc. reports results for the quarter ended June 30Earnings Summary - TradingView
Aclaris Therapeutics (ACRS) Reports Q2 Loss, Tops Revenue Estimates - finance.yahoo.com
Earnings Flash (ACRS) Aclaris Therapeutics, Inc. Reports Q2 Revenue $1.6M, vs. FactSet Est of $1.4M - marketscreener.com
Earnings Flash (ACRS) Aclaris Therapeutics Posts Q2 Net Loss $0.15 a Share, vs. FactSet Est of $0.16 Loss - marketscreener.com
Aclaris Therapeutics reports Q2 2026 net loss of $21.5M, cash runway through 2028 - TradingView
ACRS: Higher net loss and R&D spend offset by strong cash reserves and major clinical milestones ahead - TradingView
Aclaris Therapeutics Inc earnings beat by $0.01, revenue topped estimates - Investing.com
Aclaris Therapeutics Q2 revenue beats analyst estimates - TradingView
BRIEF-Aclaris Therapeutics Q2 Net Income USD -21.505 Million Vs. IBES Estimate USD -21.3 Million - TradingView
Aclaris Therapeutics 2Q Loss/Shr 15c >ACRS - Moomoo
Aclaris Therapeutics (NASDAQ: ACRS) CSO gets shares, some withheld - Stock Titan
Aclaris Therapeutics (NASDAQ:ACRS) Sets New 1-Year HighStill a Buy? - marketbeat.com
Aclaris Therapeutics Inc expected to post a loss of 16 cents a shareEarnings Preview - TradingView
Aclaris Therapeutics (ACRS) Projected to Post Quarterly Earnings on Thursday - marketbeat.com
Aclaris Therapeutics Inc (ACRS) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Aclaris Therapeutics Inc (ACRS) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Aclaris Therapeutics Inc (ACRS) Cash Flow - TradingKey
Kalehua Capital Management LLC Makes New $6.87 Million Investment in Aclaris Therapeutics, Inc. $ACRS - marketbeat.com
Aclaris Therapeutics Inc (ACRS) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
ACRS|Aclaris Therapeutics Inc|Price:5.380|Chg%:+0.150 - TradingKey
Bollard Group LLC Reduces Position in Aclaris Therapeutics, Inc. $ACRS - MarketBeat
Aclaris Therapeutics, Inc. Revenue Breakdown – NASDAQ:ACRS - TradingView
Aclaris Therapeutics Inc (ACRS) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Monashee Investment Management LLC Invests $1.88 Million in Aclaris Therapeutics, Inc. $ACRS - marketbeat.com
Aclaris Therapeutics (NASDAQ:ACRS) Reaches New 52-Week HighHere's Why - marketbeat.com
Piper Sandler Reaffirms Their Buy Rating on Aclaris Therapeutics (ACRS) - The Globe and Mail
Piper Sandler Maintains Aclaris Therapeutics(ACRS.US) With Buy Rating, Maintains Target Price $11 - Moomoo
Aclaris Therapeutics Inc Azioni (ACRS) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.52%
0.07%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):